Multicenter Phase II sequential study of S-1/Oxaliplatin (SOX) and Bevacizumab as first line therapy followed by S-1/Irinotecan (IRIS) and Cetuximab as second line in patients with metastatic colorectal cancer. : A SOBIC study
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: 1st line SOX+BV 2nd line IRIS+Cmab IRIS+Bmab IRIS Primary outcome(s): Second PFS (progression-free survival) Study Design: Single arm Non-randomized
创建时间：
2010-05-15
